Lumexa Imaging Holdings, Inc. (LMRI)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$12.18+2.35%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · LMRI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
No current thesis-health read is available for this company.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 24.8% |
| Our one-year growth estimate | diamond | 79.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 55.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has been missing across recent quarters and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 88 industry peers · Company calendar date is not available
LMRI — credit agreement
Dated 2026-06-30
Entry into a Material Definitive Agreement. On June 30, 2026, Lumexa Imaging, Inc. and Lumexa Imaging Outpatient, Inc. (collectively, the “ Borrowers ”), each an indirect wholly-owned subsidiary of Lumexa Imaging Holdings, Inc. (the “ Company ”), the other Loan Parties party thereto, the Lenders party thereto and Barclays Bank PLC, as administrative agent, entered into an amendment to their existing Credit Agreement (as so amended, the “ Amended Credit Agreement ”). Capitalized terms used her…
Why it matters: A slowdown in revenue growth could indicate broader issues in the healthcare sector.
Worry ifRevenue growth falls below its historical average. This could mean trouble.
Less concerning ifRevenue growth stays stable or gets better. This suggests continued strength.
Why it matters: This growth rate is key to understanding demand for Lumexa's services. A drop below 5% may signal weakening demand.
Worry ifQ3 outpatient imaging growth was less than 5%.
Less concerning ifQ3 outpatient imaging growth was more than 5%.
Why it matters: This growth rate is important to judge how well the company is doing.
Worry ifQ2 same-center volume growth was under 5%.
Less concerning ifQ2 same-center advanced volume growth was at or above 5%.
Why it matters: A rise in net income shows better operations. It also means better financial health.
Supportive ifNet income for Q2 exceeds $1.7 million.
Worry ifNet income for Q2 is less than $1.7 million.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$211 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $650 loss on $10,000 · 6.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,346 loss on $10,000 · 63.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Another earnings miss could signal ongoing issues with revenue growth and investor confidence. This is critical to monitor.
Worry ifEarnings report shows results that meet or beat expectations. This reverses the trend of misses.
Less concerning ifAnother earnings miss reported. This confirms ongoing revenue problems.
Why it matters: This report shows if Lumexa is on track to meet its $1.045 to $1.097 billion revenue goal for 2026. A strong report could boost investor confidence.
Supportive ifQ2 revenue is over $300 million. This shows strong progress toward the annual target.
Worry ifQ2 revenue is under $250 million. This shows challenges in reaching the annual revenue goal.
Why it matters: If Lumexa misses earnings again, investors may worry about its financial goals. This could lead to negative feelings.
Worry ifQ2 results show an earnings miss similar to the previous quarters.
Less concerning ifQ2 results show an earnings beat. This means better financial performance.
Why it matters: New centers are key to Lumexa's growth strategy and achieving its expansion goals.
Supportive ifAnnouncement of at least 2 more de novo centers by August 2026.
Worry ifNo new de novo centers announced by August 2026.
Why it matters: If the health care sector shows better performance, it could benefit Lumexa Imaging. A stronger sector may support its stock price.
Supportive ifHealth care sector performance improves to a positive regime score.
Worry ifThe health care sector is doing worse. It has a negative regime score.
Why it matters: Falling below this mark could mean trouble in making money.
Worry ifAdjusted EBITDA for 2026 was less than $234 million.
Less concerning ifAdjusted EBITDA for 2026 was at or above $234 million.
Why it matters: Meeting or exceeding this growth shows Lumexa is on track to hit its annual revenue target.
Supportive ifQ3 consolidated revenue growth of 5% or more year over year.
Worry ifQ3 consolidated revenue growth below 5% year over year.
Why it matters: Staying in this range shows Lumexa is keeping costs low while growing. This is key for making more money.
Supportive ifAdjusted EBITDA reported in Q3 falls within the $235 to $241 million range.
Worry ifAdjusted EBITDA reported in Q3 is outside the $235 to $241 million range.
Why it matters: New centers show growth and expansion. This is important for Lumexa's plans and future income.
Supportive ifAnnouncement of at least two new imaging centers in Q3.
Worry ifNo new imaging centers announced in Q3.
Why it matters: This growth shows Lumexa can increase demand at existing centers. This is vital for stability.
Supportive ifIn Q3, advanced outpatient volume growth at the same center was over 5%.
Worry ifIn Q3, advanced outpatient volume growth at the same center was below 5%.